2. Search Result
Search Result
Results for "

DME

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-140163
    N,N'-DME-N-PEG2-Boc

    		PROTAC Linkers Cancer
    N,N'-DME-N-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
    N,N'-DME-N-PEG2-Boc
  • HY-150069
    UBX1325

    		Bcl-2 Family Apoptosis Metabolic Disease
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
    UBX1325
  • HY-P99116
    Faricimab

    RG7716; RO-6867461

    		 VEGFR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
    Faricimab
  • HY-P99830
    Conbercept

    KH902

    		 VEGFR TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology Cancer
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
    Conbercept
  • HY-141028
    N,N'-DME-N,N'-Bis-PEG2-acid

    		PROTAC Linkers Cancer
    N,N'-DME-N,N'-Bis-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
    N,N'-DME-N,N'-Bis-PEG2-acid
  • HY-N9535A
    (R)-tert-OMe-byakangelicin

    		Drug Metabolite Metabolic Disease
    (R)-tert-OMe-byakangelicin is a kind of furanocoumarin, which has inhibitory activity to liver drug metabolizing enzyme (DME) activity. (R)-tert-OMe-byakangelicin can be isolated from immature fruits of Angelica sinensis .
    (R)-tert-OMe-byakangelicin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: